tiprankstipranks
Daxor Corp (DE:DX5)
FRANKFURT:DX5
Germany Market
DX5
Daxor
RESEARCH TOOLSreports

Daxor (DX5) Earnings Dates, Call Summary & Reports

4 Followers

Earnings Data

Report Date
Aug 20, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.03
Last Year’s EPS
-0.06
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a robust performance with significant revenue growth, successful strategic acquisitions, and expanded clinical partnerships. Despite a delay in FDA approval and a decrease in unrealized appreciation, the company showcased strong momentum and promising developments for the future.
Company Guidance
During the Daxor Corporation Conference Call for the 2024 fiscal year, management provided several key financial and operational metrics. As of December 31st, 2024, the company's net assets increased to $36,789,893 or $7.25 per share, compared to $34,010,384 or $7.08 per share at the end of 2023. The company's net income included net dividend income of $104,115 and net realized gains on investments of $1,359,163, offset by a net decrease in unrealized appreciation of $1,148,350. The company invested $1,614,124 into its operating division for research and development, sales, and production facilities in anticipation of a 2025 product launch. Additionally, Daxor achieved a cash flow breakeven in early 2025, excluding costs related to stock-based compensation, depreciation, amortization, or CapEx. Revenue increased by 116.5% from 2023 to 2024, with a further year-on-year increase of over 100% in the first two months of 2025. The company also reported significant clinical progress with the adoption of its Blood Volume Analyzer (BVA) technology across various medical disciplines, laying the groundwork for further growth and innovation in healthcare solutions.
Increase in Net Asset Value
Daxor's net assets increased from $34,010,384 in 2023 to $36,789,893 in 2024, reflecting a rise in net asset value per share from $7.08 to $7.25.
Significant Revenue Growth
Revenue increased by 116.5% year-on-year from 2024 versus 2023. In the first two months of 2025, revenue is over 100% higher than the same period in 2024.
Expansion of Clinical Partnerships
Daxor expanded into community hospital systems and formed strong relationships with various medical specialists, resulting in broader use of their technology.
FDA Submission for Next-Generation Analyzer
Daxor completed a multicenter study for its next-generation analyzer. They plan to resubmit a 510(k) application for a 90-day review.
Strategic Acquisitions
Daxor acquired rights to manufacture Volumex and Megatope and added Glofil to their product suite, expected to be cash flow positive and accretive.
Successful Funding and Contracts
Received a $2.5 million DoD contract and additional NIH grants totaling over $350,000.

Daxor (DE:DX5) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

DE:DX5 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 20, 2026
2026 (Q2)
-0.03 / -
-0.063―――
Mar 03, 2026
2025 (Q4)
- / 1.62
0.377329.38% (+1.24)――
Aug 21, 2025
2025 (Q2)
- / -0.06
-0.33581.03% (+0.27)――
Mar 06, 2025
2024 (Q4)
- / 0.38
0.592-36.38% (-0.22)―
Aug 22, 2024
2024 (Q2)
- / -0.29
-0.58350.29% (+0.29)――
Mar 18, 2024
2023 (Q4)
- / 0.59
1.473-59.81% (-0.88)――
Aug 24, 2023
2023 (Q2)
- / -0.58
-0.385-51.45% (-0.20)――
Mar 02, 2023
2022 (Q4)
- / 1.47
1.33810.06% (+0.13)―
Aug 25, 2022
2022 (Q2)
- / -0.39
-0.329-16.93% (-0.06)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:DX5 Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 03, 2026
€10.40€10.00-3.85%
Aug 21, 2025
€8.75€8.95+2.29%
Mar 06, 2025
€6.75€7.00+3.70%
Aug 22, 2024
€7.45€7.40-0.67%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Daxor Corp (DE:DX5) report earnings?
Daxor Corp (DE:DX5) is schdueled to report earning on Aug 20, 2026, After Close (Confirmed).
    What is Daxor Corp (DE:DX5) earnings time?
    Daxor Corp (DE:DX5) earnings time is at Aug 20, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Daxor Corp stock?
          The P/E ratio of Daxor is N/A.
            What is DE:DX5 EPS forecast?
            DE:DX5 EPS forecast for the fiscal quarter 2026 (Q2) is -0.03.